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For the last 20 years, cellular biologists have been focusing on the role of Ras
signaling pathway in neurofibromatosis 1(NF1) and its lethal derivation, ma-
lignant peripheral nerve sheath tumors (MPNST). While our team has worked
on the influence of Ras pathway on responsiveness of MPNST cells to therapy,
we introduced a novel cell signaling pathway down-stream of Ras, i.e. Ral
pathway, as an important regulator of the biological features of MPNST
with potentials for being targeted for treatment of this malignancy. We have
also showed that RalA is overactivated in the cancer stem cell (CSC) fraction
of MPNST tumors establishing this pathway to harbor potentials for targeting
MPNST CSCs. In summary our preliminary data shed light on following facts:
1- RalA signaling pathway is overactivated in differentiated MPNST cells and
human tissues. 2- RalA overactivation is a characteristic of MPNST cancer
stem cells. 3- RalA inhibition hinders the malignant phenotype of MPNST
cells. 4- Disruption of RalA signaling results in loss of viability and invasion
of MPNST cells. In this presentation, we further evaluate the mechanism of
RalA overactivation and in-vivo potentials of its inhibition as a therapeutic
strategy for MPNST.
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